Press Releases Geron Corporation

Equities

GERN

US3741631036

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
3.545 ^USD	+2.16%		+1.87%	+68.01%

May. 03	Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating	MT
May. 02	Geron Shares Decline After Q1 Loss Widens	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 16	BU
Geron : Population pharmacokinetics of imetelstat, a first in class oligonucleotide telomerase inhibitor	May. 06	PU
Geron: Q1 Earnings Snapshot	May. 02	AQ
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights	May. 02	BU
WiSA Technologies (NASDAQ: WISA) Set to Revolutionize Home Audio: Strategic Moves and New Partnerships Signal Strong Market Position	Apr. 30	AQ
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024	Apr. 25	BU
Geron Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Apr. 19	AQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 18	BU
Geron to Participate at Upcoming Investor Conferences in April	Apr. 03	BU
Geron : Fiscal Year 2023 Annual Report	Mar. 28	PU
Geron : Fiscal Year 2024 Proxy	Mar. 28	PU
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	Mar. 19	BU
Geron : Risk Factor Summary - Form 8-K	Mar. 19	PU
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit, Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS	Mar. 15	AQ
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS	Mar. 14	BU
Geron: Q4 Earnings Snapshot	Feb. 28	AQ
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	Feb. 28	BU
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 22	BU
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024	Feb. 14	BU
Geron Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Jan. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Geron Corporation

Equities

GERN

US3741631036

Press Releases

Filters